Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00744276 · ClinicalTrials.gov registry record · Phase 2
A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease
A Phase 2 study, sponsored by FemmePharma Global Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00744276: Completed Phase 2 study, sponsored by FemmePharma Global Healthcare.
NCT00744276 is a Phase 2 study that has completed, run by FemmePharma Global Healthcare. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00744276, a Phase 2 study, has completed, sponsored by FemmePharma Global Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of three doses of topically applied danazol compared to placebo in subjects with pain associated with fibrocystic breast disease and to determine the appropriate clinical dose for future studies.
Interventions
- DRUG Placebo
- DRUG danazol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
What the finished NCT00744276 record still lists
NCT00744276 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00744276 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00744276 about?
NCT00744276 is a clinical study titled "A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease". The purpose of this study is to determine the safety of three doses of topically applied danazol compared to placebo in subjects with pain associated with fibrocystic breast disease and to determine the appropriate clinical dose for future studies.
What is the current status of trial NCT00744276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2007-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00744276?
The interventions under investigation include: Placebo (DRUG), danazol (DRUG).
Who is sponsoring clinical trial NCT00744276?
This trial is sponsored by FemmePharma Global Healthcare, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00744276's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia